{"id":13249,"date":"2024-11-21T00:43:38","date_gmt":"2024-11-20T17:43:38","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=13249"},"modified":"2024-11-21T00:43:38","modified_gmt":"2024-11-20T17:43:38","slug":"gbi-biomanufacturing-expands-capabilities-with-automated-aseptic-fill-finish-for-drug-products","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=13249","title":{"rendered":"GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PLANTATION, Fla.<\/span><\/span>, Nov. 21, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0GBI Biomanufacturing (GBI)<\/a>, one of the world’s longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP) services<\/a>,\u00a0to include automated sterile fill and finish capabilities. GBI has the ability to support clients from clinical trials to commercial<\/a>\u00a0launch, for both\u00a0Drug Substance (DS) and DP<\/a>, all at its one location in Florida, USA<\/span>. This addition demonstrates GBI’s commitment to delivering advanced and flexible Single-Source Solutions\u2122 for the rapidly evolving pharmaceutical and biotech industries.<\/p>\n

The ability to provide an in-house, dual approach of automated and manual sterile fill finish<\/a>, enables GBI<\/a> to meet the diverse needs of its clients with precision and efficiency. For smaller, early-stage clinical batches or products requiring special handling, manual aseptic vial filling<\/a>\u00a0offers flexibility and control. Automated aseptic liquid filling<\/a> employing ready-to-use components supports higher-throughput production with minimal human intervention, reducing the risk of contamination and increasing batch consistency, making it ideal for both clinical and commercial-scale projects.<\/p>\n

“Adding automated aseptic fill-finish<\/a> capabilities to our service offerings strengthens our ability to meet the diverse requirements of our clients, from start-up biotech to established pharmaceutical companies,” said Karl Pinto<\/span><\/a>, & CEO at\u00a0GBI. “Our facility<\/a> is equipped with state-of-the-art technology and a team of experts, capable of delivering high-quality, regulatory compliant drug products.”<\/p>\n

GBI’s new three format automated filler has capabilities to support filling in vials, syringes and cartridges, across various drug classes such as biologics, vaccines, bioconjugates<\/a>\u00a0and complex large molecules<\/a>.<\/p>\n

The addition of these capabilities aligns with GBI’s broader mission to provide its clients with end-to-end development and cGMP manufacturing<\/a> services as a Single-Source Solution\u2122\u00a0CDMO. The company’s enhanced fill-finish<\/a> capacity will simplify its clients’ manufacturing supply chains and help in achieving faster timelines<\/a>, improved scalability, regulatory compliance and the convenience of having both\u00a0DS and DP material manufactured at one site<\/a>!<\/p>\n

About GBI<\/b><\/p>\n

GBI is a leading CDMO focused on providing comprehensive, high-quality services to the global pharmaceutical and biotech sectors. With expertise in process development<\/a>, analytical services<\/a>, DS manufacturing and sterile fill finish<\/a>\u00a0for biologics, GBI supports the development and commercialization<\/a>\u00a0of life-saving therapies worldwide.<\/p>\n

For more information on GBI, a drug substance and sterile fill finish CDMO visit: https:\/\/www.gbibio.com\/aseptic-fill-finish\/<\/a> or contact via\u00a0https:\/\/www.gbibio.com\/contact\/<\/a>.<\/p>\n

Media Contact: info@GbiBio.com<\/a>\u00a0<\/p>\n

Logo – https:\/\/mma.prnasia.com\/media2\/2523494\/GBI_Biomanufacturing.jpg?p=medium600<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PLANTATION, Fla.<\/span><\/span>, Nov. 21, 2024<\/span><\/span> \/PRNewswire\/ —\u00a0GBI Biomanufacturing (GBI)<\/a>, one of the world’s longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP) services<\/a>,\u00a0to include automated sterile fill and finish capabilities. GBI has the ability to support clients from clinical trials to commercial<\/a>\u00a0launch, for both\u00a0Drug Substance (DS) and DP<\/a>, all at its one location in Florida, USA<\/span>. This addition demonstrates GBI’s commitment to delivering advanced and flexible Single-Source Solutions\u2122 for the rapidly evolving pharmaceutical and biotech industries.<\/p>\n

The ability to provide an in-house, dual approach of automated and manual sterile fill finish<\/a>, enables GBI<\/a> to meet the diverse needs of its clients with precision and efficiency. For smaller, early-stage clinical batches or products requiring special handling, manual aseptic vial filling<\/a>\u00a0offers flexibility and control. Automated aseptic liquid filling<\/a> employing ready-to-use components supports higher-throughput production with minimal human intervention, reducing the risk of contamination and increasing batch consistency, making it ideal for both clinical and commercial-scale projects.<\/p>\n

“Adding automated aseptic fill-finish<\/a> capabilities to our service offerings strengthens our ability to meet the diverse requirements of our clients, from start-up biotech to established pharmaceutical companies,” said Karl Pinto<\/span><\/a>, & CEO at\u00a0GBI. “Our facility<\/a> is equipped with state-of-the-art technology and a team of experts, capable of delivering high-quality, regulatory compliant drug products.”<\/p>\n

GBI’s new three format automated filler has capabilities to support filling in vials, syringes and cartridges, across various drug classes such as biologics, vaccines, bioconjugates<\/a>\u00a0and complex large molecules<\/a>.<\/p>\n

The addition of these capabilities aligns with GBI’s broader mission to provide its clients with end-to-end development and cGMP manufacturing<\/a> services as a Single-Source Solution\u2122\u00a0CDMO. The company’s enhanced fill-finish<\/a> capacity will simplify its clients’ manufacturing supply chains and help in achieving faster timelines<\/a>, improved scalability, regulatory compliance and the convenience of having both\u00a0DS and DP material manufactured at one site<\/a>!<\/p>\n

About GBI<\/b><\/p>\n

GBI is a leading CDMO focused on providing comprehensive, high-quality services to the global pharmaceutical and biotech sectors. With expertise in process development<\/a>, analytical services<\/a>, DS manufacturing and sterile fill finish<\/a>\u00a0for biologics, GBI supports the development and commercialization<\/a>\u00a0of life-saving therapies worldwide.<\/p>\n

For more information on GBI, a drug substance and sterile fill finish CDMO visit: https:\/\/www.gbibio.com\/aseptic-fill-finish\/<\/a> or contact via\u00a0https:\/\/www.gbibio.com\/contact\/<\/a>.<\/p>\n

Media Contact: info@GbiBio.com<\/a>\u00a0<\/p>\n

Logo – https:\/\/mma.prnasia.com\/media2\/2523494\/GBI_Biomanufacturing.jpg?p=medium600<\/a><\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-13249","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/13249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13249"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/13249\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}